

Capsules
One capsule contains:
cytidine-5´-monophosphate disodium salt - 5 mg
uridine 5´-trisodium triphosphate, uridine 5´-disodium diphosphate, uridine 5´-disodium monophosphate - 3 mg (which corresponds to 1.33 mg of pure uridine)
citric acid, sodium citrate dihydrate, Magnesium stearate, aerosil 200, mannitol.
ferric oxide black (E 172), titanium dioxide (E 171), indigo carmine (E 132), gelatin.
Hard gelatin capsules with an opaque body of gray flowers and a blue lid. The contents of the capsules are white hygroscopic powder.
Other drugs for the treatment of diseases of the nervous system
Pharmacokinetics
Keltikan is a combination of two nucleotides-cytidine monophosphate and uridine monophosphate. These nucleotides are present in the organism, so it is not possible to conduct a typical pharmacokinetic study.
Keltikan® provides the body with phosphate groups necessary to combine monosaccharides with ceramics to form the nerve shells, and phosphatidic acids,The components of the sphingomyelin Iglycerophospholipids are the main components of the myelin sheath. Thus, a steady trophic effect, more complete maturation and regeneration of axonal nerve fibers are provided. As a result, inflammation decreases and the sensitivity of the damaged part of the axon is normalized, which contributes to the restoration of axonal transport.
- radiculitis (lumbago, lumbodynia, lumbar ischialgia)
- diabetic polyneuropathy
- alcoholic polyneuritis
- shingles, ganglionitis
- inflammation of the trigeminal nerve, neuralgia of the facial, trigeminal,
intercostal nerves
- plexites.
Keltikan® capsules are taken orally.
Adults: 1-2 capsules 2 times a day.
Children over 5 years: 1 capsule 2 times a day.
Keltikan® can be taken before or after meals.
The recommended duration of treatment is at least 10 days. If necessary, the capsules can be continued for 20 days, if the doctor deems it necessary.
It has not been described.
Perhaps the manifestation of allergic reactions, in the case of manifestation of any adverse events, you should suspend the reception and always consult a doctor.
hypersensitivity to the drug
children up to 5 years
Not installed.
Pregnancy and lactation
The use of the drug during pregnancy and lactation is not contraindicated, but the feasibility of taking and the dose of the drug is determined by the doctor, depending on the benefits of the use of the drug over the potential risk to the fetus / child.
Features of the effect of the drug on the ability to drive a vehicle or potentially dangerous machinery
Keltikan does not affect the ability to drive vehicles and perform work related to
the need for concentration.
Due to the low toxicity of the drug overdose is unlikely.
Store at a temperature not higher than 30 ° C.
Keep out of the reach of children!
Do not use after the expiration date printed on the package.